Methods and systems for inhibiting foreign-body responses in diabetic patients

• US 10,517,892 B2
• Filed: 10/13/2014
• Issued: 12/31/2019
• Est. Priority Date: 10/22/2013
• Status: Active Grant

• Current Assignee: Medtronic Minimed Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Minimed Incorporated (Medtronic Plc)
• Inventors: Chattaraj, Sarnath, Dang, Kiem H., Fusselman, Hsi Chung, Gulati, Poonam S., Hoffman, Lance P., Zhang, Guangping
• Primary Examiner(s): Farrar, Lauren P
• Application Number:
  US14/512,788
• Publication Number:
  US 20150112302A1
• Time in Patent Office: 1,905 Days
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61L 2300/236 Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61M 2005/1586 Holding accessories for holding infusion needles on the body
• CPC Class Codes: A61M 2205/0205 Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
• CPC Class Codes: A61M 2205/0238 the material being a coating or protective layer
• CPC Class Codes: A61M 5/14248 of the skin patch type
• CPC Class Codes: A61M 5/158 Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
• CPC Class Codes: A61M 5/16827 controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths infusion of multiple fluids without using a controller A61M5/1407
• CPC Class Codes: A61M 5/16836 by sensing tissue properties at the infusion site, e.g. for detecting infiltration detecting tissue temperature for diagnostic purposes A61M39/0247
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

Methods and devices are provided for reducing a diabetic patient'"'"'s foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

Claims

1. A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising:

a medication reservoir comprising an insulin solution;

a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;

a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion; and

a heparin composition in operable contact with the fluid conduit that inhibits inflammation at the single site of infusion so as to inhibit insulin site loss; and

wherein the system delivers an amount of heparin sufficient to inhibit inflammation at the single site of infusion for a period of time of at least 4 days.

2. The system of claim 1, wherein the heparin composition:

(a) is disposed within a depot and adapted to contact the insulin solution as the insulin solution flows from the medication reservoir to the single site of infusion; and

/or

(b) is pre-or in-situ mixed with insulin.

3. The system of claim 2, wherein the depot includes a membrane and/or a filter and/or a sponge and/or a polymeric material and/or a metal comprising heparin.

4. The system of claim 2, wherein the heparin is administered to the patient in an amount between 0.1 and 80 U/kg/day.

5. The system of claim 2, wherein the system further delivers heparin according to at least one delivery profile including:

(a) an immediate release profile wherein the heparin is administered to the patient from 0 to 6 hours following insertion of the cannula; and

(b) an extended release profile wherein the heparin is administered to the patient for at least 48 hours following insertion of the cannula.

6. The system of claim 1, wherein the system further comprises dextran adapted to contact the insulin solution.

7. The system of claim 6, wherein the dextran is administered to the patient at a concentration between 0.0005 and 0.4 mg/kg/day.

8. The system of claim 1, wherein the heparin:

(a) coats the fluid path including cannula; and

/or

(b) coats a septum and/or the inner surface within the medication reservoir.

9. A method for mitigating a foreign body response in a diabetic patient receiving insulin at a single infusion site over a time period of at least three days, the method comprising:

administering a site loss mitigating agent comprising heparin in combination with insulin at the single infusion site so as to inhibit insulin site loss, wherein the site loss mitigating agent mitigates inflammation at the single infusion site thereby inhibiting a foreign body response in a diabetic patient; and

wherein the system delivers an amount of a site loss mitigating agent sufficient to inhibit inflammation at the single site of infusion for at least 4 days.

10. The method of claim 9, wherein the site loss mitigating agent is heparin administered at a concentration range of 40 U/ml to 8000 U/ml or 0.1 mg/ml to 20 mg/ml.

11. The method of claim 9, wherein the heparin is combined with the insulin prior to delivery of the insulin.

12. The method of claim 9, wherein the heparin:

is disposed in a depot adapted to contact an insulin solution as the insulin solution flows from a medication reservoir to the single infusion site;

is disposed on the cannula;

is disposed in a transdermal patch that secures the infusion set to the patient; and

/or

is disposed in a drug-coated septum and/or inside surface within a reservoir of an insulin pump.

13. The method of claim 9, further including administering dextran, sirolimus, tacrolimus, or combination thereof.

14. A method for delivering insulin to a diabetic patient at a single site of infusion over a period of at least four days, the method comprising infusing the insulin at the single site of infusion using a system comprising:

a medication reservoir comprising an insulin solution;

a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;

a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion;

heparin that inhibits-inflammation at the single site of infusion so as to inhibit insulin site loss;

so that insulin is delivered to the diabetic patient; and

wherein the heparin is administered according to an extended release profile that delivers heparin to the single site of infusion in a manner sufficient to inhibit inflammation at the single site of infusion for at least 6 days.

15. The method of claim 14, wherein the heparin is administered in an amount between 40 U/ml to 8000 U/ml and at a dose of 0.1 to 80 U/kg/day.

16. The method of claim 14, further comprising administering dextran in an amount between 0.0005-0.4 mg/kg/day.

17. The method of claim 14, wherein the heparin is disposed within a depot and adapted to contact the insulin solution as the insulin solution flows from the medication reservoir to the single site of infusion.

18. A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising:

a medication reservoir comprising an insulin solution;

a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;

a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion; and

a site loss mitigation composition disposed in operable contact with the fluid conduit inflammation at the single site of infusion so as to inhibit insulin site loss; and

wherein the site loss mitigation composition comprises heparin in an amount sufficient to administer between 0.1 and 80 U/kg/day to the diabetic patient so as to inhibit site loss in the diabetic patient for at least 4 days.

19. The system of claim 18, wherein the site loss mitigation composition comprises heparin in an amount sufficient to inhibit site loss for at least 6 days.

20. The system of claim 19, wherein the site loss mitigation composition comprises dextran in an amount sufficient to administer between 0.0005 and 0.4 mg/kg/day to the diabetic patient.

21. The system of claim 20, wherein the system delivers at least 50% of the heparin administered in the first three days following insertion of the cannula at the single site of infusion.

22. The system of claim 19, wherein the system delivers heparin according to at least two delivery profiles including:

(a) an immediate release profile wherein the heparin is administered to the patient from 0 to 6 hours following insertion of the cannula; and

(b) an extended release profile wherein the heparin is administered to the patient for at least 48 hours following insertion of the cannula.